Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Holding RIGL?
Track your performance easily
RIGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.12 - $17.29
Previous Close$13.68
Volume64.15K
Average Volume (3M)174.63K
Market Cap
$240.70M
Enterprise Value$251.93M
Total Cash (Recent Filing)$49.10M
Total Debt (Recent Filing)$60.33M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 05, 2024EPS Estimate
$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding17,594,977
10 Day Avg. Volume85,524
30 Day Avg. Volume174,634
Standard Deviation0.24
R-Squared0.04
Alpha0.00742
Financial Highlights & Ratios
Price to Book (P/B)-8.02
Price to Sales (P/S)1.85
Price to Cash Flow (P/CF)199.30
P/FCF Ratio28.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-176.92
Forecast
1Y Price Target
$37.00Price Target Upside171.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Rigel News
Bulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsThe recent collaborations are expected to test Rezlidhia in additional IDH1-mutant cancers, potentially driving future revenue growth.
Financial PerformanceRigel announced 4Q23 and 2023 full year financial results, posting EPS of $0.00 and ($0.14), respectively, exceeding analysts’ estimates.
Product SalesSales of Rezlidhia for IDH1m r/r AML increased by ~29% QoQ to $4.9M, which was above the analyst's expectations.
Bears Say
EarningsRigel posted EPS of ($0.05) compared to the estimate of ($0.03).
Product SalesTavalisse sales in ITP decreased by 18% QoQ to $21.1M, falling below the estimate.
RevenueRevenue for the quarter was $29.5 million, below the estimate of $31.68 million.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.12 and its highest was $17.29 in the past 12 months.
What is Rigel’s market cap?
Currently, no data Available
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 06, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.292 by $0.232.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is $0.06.
How many shares outstanding does Rigel have?
Rigel has 17,594,976 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.292. Following the earnings report the stock price went up 5.788%.
Which hedge fund is a major shareholder of Rigel?
Among the largest hedge funds holding Rigel’s share is Graham Capital Management, L.P.. It holds Rigel’s shares valued at N/A.
---
Rigel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (171.46% Upside)
$37.00 (171.46% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.67%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q2 2024
0:00 / 0:00
---
RIGL Stock 12 Month Forecast
Average Price Target
$37.00
▲(171.46% Upside)
Technical Analysis
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+14.81%
reiterated a buy rating 16 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +14.81% per trade.
---